Journal of Biopharmaceutical Statistics

The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to such work in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:

• Drug, device, and biological research and development
  
• Drug screening and drug design
  
• Assessment of pharmacological activity
  
• Pharmaceutical formulation and scale-up
  
• Preclinical safety assessment
  
• Bioavailability, bioequivalence, and pharmacokinetics
  
• Phase, I, II, and III clinical development
  
• Premarket approval assessment of clinical safety
  
• Postmarketing surveillance
  

Peer Review Policy
All submitted manuscripts are subject to initial appraisal by the Editor, and if found suitable for further consideration, will be peer-reviewed by independent and anonymous expert referees. All peer review is double blind and submission is online via https://mc.manuscriptcentral.com/lbps

Publishing Ethics Statement
The Journal adheres to the highest standards of publishing ethics, with rigorous processes in place to ensure this is achieved. Taylor & Francis is a member of Committee of Publication Ethics (COPE) and utilizes Similarity Check via CrossRef for all journals. More information on our ethical standards and policies can be found here: http://authorservices.taylorandfrancis.com/ethics-for-authors/.
The Journal has an appeals and complaints policy which can be viewed here: https://authorservices.taylorandfrancis.com/peer-review-appeals-and-complaints-from-authors/.

Publication office: Taylor & Francis, Inc., 530 Walnut Street, Suite 850, Philadelphia, PA 19106.